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Abstract
Background: Most cases of idiopathic autism spectrum disorder (ASD) likely result from unknown environmental
triggers in genetically susceptible individuals. These triggers may include maternal exposure of a fetus to minute
concentrations of pharmaceuticals, such as carbamazepine (CBZ), venlafaxine (VNX) and fluoxetine (FLX).
Unmetabolized pharmaceuticals reach drinking water through a variety of routes, including ineffectively treated
sewage. Previous studies in our laboratory examined the extent to which gene sets were enriched in minnow
brains treated with pharmaceuticals. Here, we tested the hypothesis that genes in fish brains and human cell
cultures, significantly enriched by pharmaceuticals, would have distinct characteristics in an ASD-associated protein
interaction network. We accomplished this by comparing these groups using 10 network indices.
Results: A network of 7212 proteins and 33,461 interactions was generated. We found that network characteristics
for enriched gene sets for particular pharmaceuticals were distinct from each other, and were different from non-
enriched ASD gene sets. In particular, genes in fish brains, enriched by CBZ and VNX 1) had higher network
importance than that in the overall network, and those enriched by FLX, and 2) were distinct from FLX and non-
enriched ASD genes in multivariate network space. Similarly, genes in human cell cultures enriched by
pharmaceutical mixtures (at environmental concentrations) and valproate (at clinical dosages) had similar network
signatures, and had greater network importance than genes in the overall ASD network.
Conclusions: The results indicate that important gene sets in the ASD network are particularly susceptible to
perturbation by pharmaceuticals at environmental concentrations.
Background
Autism is a complex neurobiological developmental dis-
order belonging to a group of conditions known as Aut-
ism Spectrum Disorder (ASD) [1,2]. ASD has an overall
prevalence of approximately one case in every 50 children
in USA [3], notably affecting four times as many males as
females [4,5]. To date, several studies have reported ASD
−associated genetic factors and have categorized them
into 2 groups: rare variants (genes with low susceptibility
and high penetrance) and common variants (genes with
high susceptibility and low penetrance) [4]. These genetic
factors, however, are responsible for only 2-3% of identi-
fied ASD cases [5,6].
In most other instances, studies suggest that ASD
results from unknown environmental triggers acting on
genetically susceptible individuals [6-9]. Susceptibility
may be associated with gene variants [9] involved in bio-
logical pathways associated with ASD such as cell adhe-
sion, synaptic vessel release, neurotransmission, and
synaptic structure [6,10,11]. These biological pathways
are inter-connected in a very complex manner [12].
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However, it is unclear how environmental contaminants
interact with or otherwise perturb ASD-associated biolo-
gical pathways [12].
Today, genetically susceptible individuals may be
exposed to combinations of 3000 synthetic chemicals via
air, food and water [8]. Synthetic chemicals are generally
categorized into two groups: pharmaceuticals and perso-
nal care products (PPCPs), and other industrial chemi-
cals, such as organophosphate insecticides and organic
solvents (e.g., ethyl alcohol) [8]. PPCPs include exten-
sively used psychoactive pharmaceuticals [13], but also
include bis-phenyl A in plastics, phthalates in cosmetics
and household products, and known teratogenic phar-
maceuticals [8]. In this study we focus on psychoactive
pharmaceuticals that 1) may find their way to drinking
water from clinical dosages excreted by patients, 2) are
generally untreated by waste-water treatment plants
[14], and 3) have sufficiently long half-lives [10] to even-
tually emerge in drinking water. Because many PPCPs
are known to perturb neurological systems, exposure of
a fetus to these contaminants by way of the pregnant
mother’s water consumption is a plausible environmen-
tal risk factor for neurological disorders like ASD [7,8].
In a previous study, we investigated psychoactive
pharmaceuticals presented at very low concentrations in
the environment [10,11]. Juvenile fathead minnows
(Pimephales promelas) were exposed to fluoxetine
(FLX), venlafaxine (VNX) and carbamazepine (CBZ)
individually and in mixtures at environmentally relevant
concentrations [11]. Using gene-class analysis [15], gene
expression data indicated enrichment (significant up- or
down-regulation) of gene sets associated with neuronal
growth, regulation, and development in the juvenile
minnow brains in response to psychoactive drug exposure
[11]. Moreover, a significant behavioral change (number of
turns, lateralization, distance travelled) was observed in
fish exposed to pharmaceuticals. We sought to identify
potential pharmaceutical-associated gene expression
mechanisms underlying these responses. As a first step,
we considered the interaction of pharmaceuticals within
the underlying ASD-associated protein network. This
approach has been used elsewhere to determine how alter-
ing expression of one or a few genes can influence biologi-
cal pathways, ultimately contributing to complex
phenotypes [16].
We found previously that fathead minnows exposed to
PPCPs had a significantly altered behavioral phenotype
compared to a non-exposed (control) group [11], and
that PPCP-enriched gene sets represented biological path-
ways, which play a major role in neuronal systems. Thus,
we predicted 1) that gene sets enriched by CBZ, VNX,
FLX and MIX (all three) contained proteins that would
be more interconnected than genes in the overall ASD-
network, and 2) that gene sets enhanced by individual
pharmaceuticals would have distinct network characteris-
tics from each other.
To address these hypotheses, we constructed a protein-
protein interaction (PPI) network of gene products known
to be associated with ASD [17,18], and examined 1) genes
enhanced by particular PPCPs in fish brains, and 2) genes
enhanced by a PPCP mixture and valproate (VPA) in
human neuronal cells. We note that VPA is known to
induce ASD-like phenotypes in mice [19]. We sought to
quantify patterns among gene sets enriched by PPCPs in
both fish brains and human cell cultures by analyzing their
network indices. Of particular interest was the identifica-
tion of relationships between PCPP treatments and highly
interconnected gene sets, as these are more likely to have
profound effects on the functioning of the protein network
because of their ripple effects on downstream proteins [20].
Results
We postulated that proteins within PPCP-enriched groups
would have both distinct network characteristics from each
other and higher levels of importance in the ASD protein-
protein network. Support of this hypothesis would suggest
that any dysregulation in the expression of PPCP-enriched
proteins would result in large impacts to the network due
to ripple effects on downstream proteins. To address this
question, we generated an ASD protein-protein interaction
network. The network consisted of 7212 nodes, with
approximately 2000 primary neighbor proteins and 5000
secondary neighbor proteins (Figure 1). The average
number of adjacent neighbors (average degree centrality;
See additional file 1) for proteins in the network was 9.279,
while the median degree centrality was 5.000. Additional
summaries of network properties are listed in additional
documents to this manuscript. (See additional file 1)
In fish brains: Carbamazepine- and Venlafaxine- enhanced
gene sets were more inter-connected in the ASD-network
than both Fluoxetine- enhanced gene sets and the non-
enriched portion of the network
When considering fish brain cells, the VNX and CBZ
groups had significantly higher location shifts (median
and pseudomedian), compared to the overall network, for
network indices widely deemed to be most important in
identifying nodal importance (i.e., degree centrality, close-
ness centrality, betweenness centrality, and stress). The
omnibus null hypothesis of equal location shifts for
groups was rejected for all four of these measures allow-
ing protected pairwise comparisons of groups [21]. In
these comparisons the CBZ and VNX groups were statis-
tically equivalent with respect to degree centrality,
betweenness centrality and stress. The CBZ and VNX
groups, however, had significant location shifts compared
to the FLX group, and significantly higher locations than
the overall ASD network (Figure 2). Strikingly, the FLX
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group degree centrality, closeness centrality, betweenness
centrality, and stress locations were less than or equal to
those of the overall ASD network (Figure 2).
The collective network characteristics of pharmaceutical
groups were considered using both permutation multivari-
ate analysis of variance (PERMANOVA) and non-metric
multidimensional scaling (NMDS). The fish brain cell
genes of the non-enriched portion of the ASD network
and individual pharmaceutical groups were significantly
different in network space (F3,1936 = 3.68, P = 0.001). In
pairwise PERMANOVA tests CBZ and VNX groups were
indistinguishable from each other (F1,123 = 1.06, P =
0.352). Both of these groups, however, were significantly
different from FLX (or essentially so) after adjustment for
family-wise type I error (CBZ vs. FLX: F1,48 = 3.08, P =
0.052; VNX vs. FLX: F1,101 = 3.69, P = 0.023). Further,
both the CBZ and VNX groups were statistically distinct
from the non-enriched portion of the ASD network (CBZ
vs. non-enriched: F1,1832 = 4.35, P = 0.020; VNX vs. non-
enriched: F1,1885 = 4.70, P = 0.012), whereas the FLX
group was not significantly different from the non-
enriched fraction of the ASD-network (F1,1811 = 2.12, P =
0.136). The basis for these results is graphically evident in
a non-metric multidimensional scaling (NMDS) dimen-
sion reduction of network space (Figure 3). We note that
the CBZ group and VNX groups have similar network
characteristics with high degree centrality, betweenness
centrality, stress, and radiality. Conversely, the FLX group
(more representative of non-enriched gene sets) had parti-
cularly small responses for these variables, but high values
for eccentricity, average shortest path length and cluster-
ing coefficient.
In human neuronal cells: mixture (CBZ, VNX, FLX) and
Valproate - enhanced gene sets were more inter-
connected than the overall network
To extend inference to human tissues, we extracted RNA
from human neuronal cells treated with a PCPP mixture
(CBZ, VNX, FLX) and valproate (VPA), and carried out
transcriptome analysis. We then compared network char-
acteristics of gene set groups, enriched by pharmaceuti-
cals, both to each other, and to the overall network.
We found that both the mixture and VPA group loca-
tions were significantly higher than the overall network
with respect to degree centrality, betweenness centrality,
and stress. The mixture and VPA groups were, however,
not statistically distinguishable from each other with
respect to these measures (Figure 4).
We rejected the omnibus null hypothesis that collective
ASD network characteristics were equal for all groups,
including the non-enriched portion of the ASD network
(F2,1690 = 2.34, P = 0.017). Pairwise differences among
groups, however, were not significant after adjustment for
family-wise type I error (VPA vs. MIX: F1,255 = 2.10, P =
0.133; VPA vs. non-enriched: F1,1876 = 2.11, P = 0.132; MIX
vs. non-enriched: F1,1690 = 2.85, P = 0.099). Characteristics
Figure 1 Protein-protein interaction network associated with ASD. The network was generated and visualized using Cytoscape v.2.8.3. Red
dots represent nodes (or, proteins) and blue lines represent edges (or, connections among nodes).
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of the VPA and mixture groups that may distinguish them
from the overall ASD network are evident in Figure 5. We
note both VPA and MIXTURE groups are split between
genes that have higher degree centrality, betweenness cen-
trality, closeness centrality, and radiality, and those–more
representative of the non-enriched portion of the ASD net-
work–that have smaller outcomes for these measures.
Discussion
Researchers have identified many abnormal level of gene
expression in the potential etiology of complex psychia-
tric disorders like ASD [4]. Due to many genetic factors
like CNV deletions, mutations, allelic exclusion, or epige-
netic silencing, the expression of synaptic proteins within
the developing brain of a fetus might get altered [4]. This
alteration in the level of synaptic proteins leads to the
formation of abnormal neuronal circuits, which has been
considered as one of the potential mechanism in ASD
[4]. Other linked and association studies have found that
these genetic factors are responsible for 2-3% of ASD
cases [5,6], suggested the role to unknown environmental
factors. Therefore, environmental factors are likely to be
a major determinant because they may interact in combi-
nation with other genetic (pleiotropic and epistatic) fac-
tors causing varying ASD disease phenotypes [20,22].
We believed that psychoactive pharmaceuticals at
environmental concentrations may dysregulate the
expression of key synaptic proteins that further disturb
the process of synaptogenesis. We carried out prelimin-
ary studies on juvenile fathead minnow fish exposed
with Carbamazepine (100 μg/l), Venlafaxine (50 μg/l)
and Fluoxetine (10 μg/l) at concentrations, which were
detected in the surface waters in US [10,11]. Interest-
ingly, along with significantly altered gene expression in
exposed fish brains, we also observed a significant beha-
vioral change in treated fish (number of turns, lateraliza-
tion, distance travelled) [10,11]. Similar work has been
done in zebrafish, which showed abnormal behavior
after exposing them with valproic acid (anticonvulsant
like carbamazepine) [16]. This suggested that psychoac-
tive pharmaceuticals at environmental concentrations
might be altering neuronal circuits by interacting with
Figure 2 Carbamazepine- and Venlafaxine- enriched gene sets were more inter-connected than Fluoxetine- enriched gene sets, and
the overall network. This figure compares network characteristics of gene sets enhanced by pharmaceuticals (CBZ, VNX, FLX) in fish brain
tissue. Bars are pseudomedians (i.e., Hodges-Lehman estimators of location) whiskers are bootstrap standard errors of pseudomedians. Location
measures with the same letter are not significantly different, using the BDM rank-based permutation procedure, after Holm’s adjustment for
simultaneous inference. Gray dashed horizontal lines are the pseudomedian values for the complete ASD network. Gray stars indicate that the
treatment locations are significantly greater than the complete network pseudomedian, using Wilcoxon one-sample rank sum tests.
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key genetic factors, thus caused different phenotypes in
fish [4,11].
In the context of fish brain tissues our primary hypoth-
esis was that human homologs of protein products of
genes in synaptic cells, perturbed by exposure of pharma-
ceuticals, would have distinct ASD network parameters.
To test this, we determined the extent to which protein
products of genes from gene sets enhanced by individual
pharmaceuticals in fish brains were interconnected in the
ASD-associated protein-protein interaction network. As
predicted, PPCP-enhanced sets had higher degree, close-
ness, betweenness and stress than the overall network.
Further, we found that CBZ and VNX groups had higher
degree centrality, closeness centrality, stress and between-
ness centrality than FLX group, and were distinct from the
FLX group and the non-enriched portion of the ASD-net-
work in multivariate network space (Figure 2 & 3). Inter-
estingly, these distinctions were reflected by behavioral
data in our previous study [11]. In this work, fish exposed
to environmental concentrations of CBZ and VNX dis-
played more agitated behavior (e.g., number of turns, later-
alization, distance travelled) than fish exposed to
environmental concentrations of FLX [11].
To extend these findings to human tissues, we cultured
and differentiated human SK-N-SH neuronal cells and
carried out transcriptome analysis after exposing them
with the mixture (CBZ, VNX, FLX) at environmental
concentrations and valproate at a clinical dosage [23].
We then identified proteins groups significantly enriched
in the presence of these pharmaceuticals, and quantified
their importance in the ASD protein-protein network.
We chose valproate (an anticonvulsant) as a treatment
because prenatal exposure is associated with childhood
autism [7]. Mixture and valproate groups had greater
importance (e.g., higher degree, closeness, stress and
betweenness) than the overall network (Figure 4 & 5).
We note that half of the genes from mixture group were
also in the valproate group (although overlapping genes
were not included in analyses). This suggests that the
PCPP mixture would induce gene expression in cell cul-
tures in a similar pattern to valproate.
Carbamazepine is a mood stabilizer and anticonvul-
sant used in conjunction with valproate to treat bipolar
disorders and epilepsy [19,24]. CBZ and VPA block
sodium channels, thus inhibit the epileptic effects in the
brain [24]. CBZ is present at very low concentrations in
Figure 3 Non-metric multidimensional scaling (NMDS) representation of significantly enhanced gene sets in fish brains. This figure
compares network characteristics of gene sets enhanced by pharmaceuticals in multivariate network space. Arrows within the scatterplot
indicate the direction of most rapid increase for an indicated variable. Arrow length is scaled by the R2 value of a multiple regression model in
which the variable in question is the response and the NMDS axis scores are explanatory variables.
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the surface waters of United States [10,11], and may dif-
fuse into groundwater [10]. Because the mixture group
(which included CBZ) and valproate perturbed similar
genes with relatively high network importance, we posit
that 1) protein products of genes from both PCPP mix-
ture and VPA serve as important nodes within the
ASD-associated network, 2) enrichment effects of clini-
cal doses of VPA are similar to those for environmental
concentrations of pharmaceutical mixtures, and 3) gene
dysregulation caused by PCPPs will have relatively pro-
found effects on ASD protein network because these
genes would effect more downstream proteins when
perturbed [20].
Conclusions
Genes connected to a large number of neighbors in the
ASD-associated protein-protein interaction network may
play an important role in neuronal growth, development,
and regulation. We found that protein products from
gene sets with enriched expression in fish brains and
human neuronal cells, due to an exposure of psychoactive
pharmaceuticals, were comparatively more inter-
connected to other neighboring proteins than protein
products of non-enriched gene sets. Thus, these genes
are more likely to experience altered expression upon
exposure to PPCPs, causing further dysregulation of the
whole interactome due to a ripple effect.
Methods
Construction of ASD-associated network
A list of 304 ASD-associated genes was retrieved from
the Autism Database (AutDB) [4,25], hereafter defined as
the ASD gene set. To construct the network, we used the
bioinformatics plugins for the Cytoscape visualization
system, freely available from http://www.cytoscape.org/
as an open source java application [17].
We used the MiMi Cytoscape plugin [26] to create the
ASD-associated network [27]. MiMi searched for protein
interactions for query genes in HPRD protein database
[27]. We examined all primary and secondary neighbors
(i.e. neighbors of neighbors) in HPRD database against
the ASD gene set. We then identified all primary and
Figure 4 PPCP MIX (CBZ, VNX, FLX) and Valproate (VPA) - enriched gene sets were more inter-connected than the overall network.
This figure compares network characteristics of gene sets enhanced by a mixture of pharmaceuticals (CBZ, VNX, FLX) and valproate (VPA) in human
cell cultures. Bars are pseudomedians (i.e., Hodges-Lehman estimators of location) whiskers are bootstrap standard errors of pseudomedians.
Location measures with the same letter are not significantly different, using the BDM rank-based permutation procedure, after Holm’s adjustment
for simultaneous inference. Gray dashed horizontal lines are the pseudomedian values for the complete ASD network. Gray stars indicate that the
treatment locations are significantly greater than the complete network pseudomedian using Wilcoxon one-sample rank sum tests.
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secondary protein interactions for the ASD gene set.
(See additional file 2).
From our previous microarray study on fish brain tis-
sue, we identified all gene sets that were significantly (a
= 0.05) enriched by the psychoactive pharmaceuticals
carbamazepine, venlafaxine and fluoxetine individually.
We merged all single gene sets that were enriched by
particular pharmaceuticals into separate groups, result-
ing in an enriched gene set for each of the pharmaceuti-
cals. (See additional file 3).
In a parallel application, we cultured and differentiated
human neuronal SK-N-SH cells with retinoic acid. After
differentiation, we treated cells with a mixture treatment
(CBZ, VNX, FLX) at environmental concentrations
[28,29]. As a positive control, we also treated cells with
Valproate at a clinical dose, 0.035 mM. We then carried
out transcriptome analysis on treated cells and identified
significantly (a = 0.05) enriched gene sets. Thus, we
defined two groups: mixture (MIX) and valproate (VPA)
containing all gene sets significantly enriched by the
corresponding treatment [23] (See additional file 4).
Network analysis with plug-ins and identifying
parameters of gene sets
We used the popular Java-based freeware package Cytos-
cape to map the ASD protein network [17]. We used the
Cytoscape plug-in, Network Analyzer [26], to summarize
the nodes of the generated network for ten network mea-
sures (See additional file 1). To this network we applied a
number of statistical approaches relatively novel in the
analysis of protein networks including recently developed
robust univariate and multivariate null hypothesis testing




Network data for most indices were characteristically
strongly positively skewed, and often contained outliers
(extreme values). This necessitated the use of robust
procedures for hypothesis testing and estimation. For
location (typical value) summaries we felt that the pseu-
domedian (Hodges-Lehman location estimator) was the
most appropriate measure [30]. For a single set of obser-
vations, the pseudomedian is simply the median of all
possible pairwise means. For a difference of two popula-
tions the pseudomedian is the median of all possible
pairs of differences, and is an unbiased estimator of
effect size from a Wilcoxon rank sum test [31].
Characteristics of treatments were considered in two
ways. First, nodal network outcomes for particular indices
were compared to the pseudomedian values of the com-
plete network using one-sample Wilcoxon rank sum tests
with upper tailed alternative hypotheses. Second, nodal
network outcomes for particular treatment were com-
pared to each other using Brunner-Dette-Munk (BDM)
rank-based permutation tests [32]. BDM tests are robust
to both non-normality and treatment heteroscedasticity
[33]. The latter is not true for conventional rank-based
permutation procedures (i.e., the Kruskal-Wallis test). In
BDM comparisons an ominbus one way layout with
three factor levels was used. If the null hypothesis of
equal population shifts was rejected, then pairwise BDM
tests comparing treatments were applied, and P-values
for these tests were corrected for family-wise type I error
using Holm’s procedure [34].
To test the null hypothesis of identical network charac-
teristics for the treatment groups, including the non-
enriched portion of the ASD-network, we used permuta-
tion multivariate analyses of variance PERMANOVAs [35].
Steinhaus dissimilarity was used for the underlying resem-
blance matrix [36]. P-values were calculated using 10,000
permutations of the vector of treatment assignments with
respect to the resemblance matrix. To depict patterns in
multivariate network space we used nonmetric multidi-
mensional scaling (NMDS; [37]). This method attempts to
reduce discrepancies (stress) in a resemblance matrix and a
mapping solution defined, in part, by a user-specified
dimensional choice. We again used Steinhaus dissimilarity
for the underlying resemblance matrix. Following the
recommendations of Kruskal and Wish [38], our NMDS
Figure 5 Non-metric multidimensional scaling (NMDS)
representation of significantly enhanced gene sets in human
cell cultures. This figure compares network characteristics of gene
sets enhanced by pharmaceuticals in mixtures and valproate in
multivariate network space. Arrows within the scatterplot indicate
the direction of most rapid increase for an indicated variable. Arrow
length is scaled by the R2 value of a multiple regression model with
the variable in question as the response variable and the NMDS axis
scores as explanatory variables.
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solutions were the lowest stress results from 20 rando-
mized starting configurations.
All statistical analyses we conducted using the statisti-
cal package R [31]. In particular, nodal summary data
were from Cytoscape using the package R-Cytoscape
[39], and estimation procedures and hypothesis tests
were run using R-base packages, and the packages asbio
[40] and vegan [41].
Additional material
Additional file 1: Description of network indices used in this paper.
This word file contained brief explanations of network indices.
Additional file 2: ASD-associated PPI network Cytoscape file. Cytoscape
compatible file of Core network is available at https://sites.google.com/a/
isu.edu/aho/ This file is in .cys format, and will be opened using
Cytoscape software. (Cytoscape software can be downloaded for free at
www.cytoscape.org).
Additional file 3: Complete gene data sets for fish and human cells
(CBZ-enriched in fish brains, VNX-enriched in fish brains, FLX-enriched in
fish brains, Mixture-enriched in human cells, Valproate-enriched in human
cells). These files are also available at https://sites.google.com/a/isu.edu/
aho/
Additional file 4: Complete data of gene sets for fish and human cells.
Excel files containing a complete data of all gene sets (CBZ-enriched in
fish brains, VNX-enriched in fish brains, FLX-enriched in fish brains,
Mixture-enriched in human cells, Valproate-enriched in human cells).
These files are available at https://sites.google.com/a/isu.edu/aho/
Additional file 5: Nodal summary statistics for gene set groups. The file
contains summary statistics for all nodes in the network. This file is
available at https://sites.google.com/a/isu.edu/aho/
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